PE’s $1.8T Tightrope: Exits, Deals, and the Next Capital Shift
From biopharma’s boom and EA’s $55B take-private to the $42B US-UK tech pact and a $10.5T allocator reshuffle—why private equity’s future hinges on flexibility.
Exit Strategies in Flux: What’s Most Attractive Now?
With IPO windows still largely shut and valuations swinging between optimism and caution, private equity sponsors are rethinking how best to exit portfolio companies.
Electric Vehicle Charging Stations Market: A Private Equity Investment Thesis
The electric vehicle (EV) revolution is no longer a distant prospect but a present reality reshaping global mobility. By 2024, more than 17 million EVs were sold worldwide, marking a 25% increase compared to 2023
The Fed’s 25 bp cut: a careful step into an uncertain fall
The Federal Reserve trimmed its benchmark rate by 25 basis points at its latest meeting, lowering the federal funds target range to 4.00%–4.25%, its first reduction since December.
Private equity is rewriting its strategy. GP-led secondaries have surged to $48B in just the first half of 2025, Advent cashed in a €4.1B exit, and add-on activity, while still dominant, shows signs of fatigue at $285B YTD.
In our latest PE150 micro-survey, we asked 130 professionals across private equity sponsors, corporate development, consulting, and investment banking a pivotal question:
Why Illiquidity May Be PE’s Greatest Advantage (The Data Says So)
Illiquidity’s edge, biotools’ exit reset, private credit’s quiet outperformance, and semiliquid AUM at $344B—the signals that matter for PE returns now.
